Actions of heparin in the atherosclerotic process.
Engelberg
H
H
California Arteriosclerosis Research Foundation, Beverly Hills 90210, USA.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy / Q000378:metabolism; D003167:Complement Activation / Q000187:drug effects; D016232:Endothelins / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism; D005340:Fibrinogen / Q000378:metabolism; D006031:Glycosylation; D006493:Heparin / Q000097:blood / Q000172:deficiency / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy / Q000503:physiopathology; D008071:Lipoprotein Lipase / Q000378:metabolism; D008074:Lipoproteins / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects; D009569:Nitric Oxide / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D012084:Renin-Angiotensin System / Q000187:drug effects
D016232:Endothelins; D008074:Lipoproteins; D017382:Reactive Oxygen Species; D009569:Nitric Oxide; D005340:Fibrinogen; D006493:Heparin; D008071:Lipoprotein Lipase